The Impact of Innovation on the Financial Performance of Pharmaceutical Enterprises in the Digital Era

Abstract

With the continuous evolution of the economic and social landscape, market competition among enterprises has intensified sharply. To establish core competitive advantages, seize market opportunities, and enhance their strategic position, firms are compelled to strengthen innovation capability, of which patents serve as the most direct and measurable indicator. Using pharmaceutical enterprises as research subjects, this study proposes research hypotheses, identifies variables, constructs classification criteria, and develops an empirical research model. Linear regression analysis is employed to examine the impact of innovation on corporate financial performance in the digital era. The empirical results indicate that innovation exerts a significant positive effect on financial performance among pharmaceutical enterprises. Moreover, compared with state-owned firms, innovation input enhances financial performance more strongly in non-state-owned enterprises. Likewise, relative to small and medium-sized firms, innovation contributes more significantly to financial performance in large enterprises. Based on these findings, this study proposes policy recommendations, including formulating reasonable innovation strategies and improving corporate innovation incentive mechanisms. These suggestions offer practical guidance for promoting innovation and improving financial performance within pharmaceutical enterprises.